<DOC>
	<DOC>NCT02131636</DOC>
	<brief_summary>This study will evaluate the safety and efficacy of AGN-199201 once daily compared to vehicle for the treatment of persistent moderate to severe facial erythema associated with rosacea.</brief_summary>
	<brief_title>Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea</brief_title>
	<detailed_description />
	<mesh_term>Rosacea</mesh_term>
	<mesh_term>Erythema</mesh_term>
	<criteria>Moderate to severe persistent facial erythema associated with rosacea. Greater than 3 inflammatory lesions on the face Current treatment with monoamine oxidase (MAO) inhibitors Raynaud's syndrome, narrow angle glaucoma, orthostatic hypotension, scleroderma or Sjogren's syndrome.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>